Key result
Long-term weight management drugs show no mortality or cardiovascular benefit in hypertension.
Why the study?
The effects of weight-reducing drugs on patient-relevant outcomes, particularly mortality and cardiovascular morbidity in people with hypertension, remain unclear.
Do long-term weight management drugs reduce all-cause mortality and cardiovascular morbidity in adults with essential hypertension?
Systematic Review (n=13,000)
Do long-term weight management drugs reduce all-cause mortality and cardiovascular morbidity in adults with essential hypertension?
There is currently insufficient evidence to determine if long-term weight-reducing drugs reduce mortality or cardiovascular morbidity in patients with hypertension.
Answers are grounded in this paper and cite their sources.
Insufficient evidence supports CV risk reduction with weight management drugs in hypertension; leaves open need for dedicated outcome trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Spary-Kainz et al. (2026) conducted a systematic review in essential hypertension (n=13,000). Long-term weight management drugs vs. placebo was evaluated on All-cause mortality, cardiovascular morbidity and adverse events. Long-term weight management drugs provided insufficient evidence for reducing mortality or cardiovascular morbidity in hypertension, with naltrexone/bupropion showing no mortality benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: